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Introduction
In the last decade, there has been a marked increase 
in the frequency of breast implantation in patients 
undergoing surgical treatment for breast cancer. The 
percentage of patients having breast reconstruction after 
a mastectomy is as high as 36.4–43.3% (NCIN 2011; 
Ilonzo et al. 2017). However, this applies to data from 
specialized treatment centers for patients with breast 
cancer. In other facilities, the percentage does not usu-
ally exceed 20% of the cases of mastectomy (Alderman 
et al. 2006). The frequency of such treatments in Poland 
is much lower. However, there is a lack of accurate data 
on the above problem on a national scale. The previous 
studies, which are yet not numerous, have shown that 
a percentage of the patients undergoing mastectomy and 
breast reconstruction may reach 22.4% (Tarkowski et al. 
2017). However, the complications that accompany the 
introduction of the implant (expander, final prosthe-
sis) remain a major challenge for oncological surgeons. 
The most frequent complications include infections; it is 
estimated that up to 29% (mean 5.8%) of breast recon-
struction surgery is complicated by infection (Phillips 
et al. 2013). Infection is cost-intensive and 70–80% of 
patients ultimately require removal of the implant (Pittet 
et al. 2005; Seng et al. 2015).
Among the risk factors for infection are associated 
diseases such as diabetes, renal failure, and skin diseases, 
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A b s t r a c t
The aim of the study was to analyze the reasons for removing implants after breast reconstruction in the course of treatment of breast cancer. 
The study involved 428 patients, who underwent a total of 648 breast reconstruction procedures using artificial implants. 47 out of 648 cases 
(7.3%) were identified in which the implant had to be removed. Of the 47 cases, 57.4% had undergone deferred reconstruction, and 42.6% 
immediate reconstruction; 27.7% had undergone pre-operative chemotherapy and radiotherapy, 27.7% pre-operative chemotherapy, and 
2.1% pre-operative radiotherapy; 6.4% were diabetic, 4.3% active smokers, and more than 50.0% had BMI greater than 25 kg/m2. In 83.0% 
of the analyzed cases, the reason for removal of the implant was infection, in 8.5% it was local recurrence of breast cancer, in 4.3% it was 
damage (leakage) of the implant, and in 2.1% it was post-operative pain. About 87.0% of infections appeared within one year of implanta-
tion; however, less than a half developed within 90 days of the reconstructive surgery, and up to 30 days only about 13.0% had appeared. 
Among the etiological agents of infections were: coagulase-negative Staphylococcus (31.3%), Staphylococcus aureus (18.7%), Enterococcus 
faecalis (9.4%), Enterobacter cloacae (18.8%), Pseudomonas aeruginosa (12.5%), Acinetobacter lwoffii (3.1%), and other Gram-negative 
fermenting rods accounted for 6.2%. Infections were the most common reason for removing the implant after breast reconstruction. and 
occurred most often as late infections (> 30 days after surgery). The time of observation for infectious complications should be at least 1 year.
K e y  w o r d s: breast cancer, implants, infections, etiological agents
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but also systemic treatment and radiotherapy. Other 
factors that increase the risk of infection include obesity 
and nicotinism. Infections are also triggered by factors 
associated with the surgery itself: an immediate breast 
reconstruction with the use of a final prosthesis is more 
often complicated by infection than deferred recon-
struction. The prolonged (> 2 h) duration of surgery 
and post-operative drainage also have an unfavorable 
effect (Pittet et al. 2005; Araco et al. 2007).
Among the etiological agents of infections, the 
most common are skin microbiota: coagulase-nega-
tive Staphylococcus, Corynebacterium spp., Propioni-
bacterium acnes, and Staphylococcus aureus, but more 
and more frequently there are reports on the increased 
proportion of Gram-negative bacteria from the order 
Enterobacterales and anaerobic microorganisms among 
etiological agents of these infections (Halvorson et al. 
2007; Weichman et al. 2013; Seng et al. 2015).
This study aimed to retrospectively analyze the 
causes of removal of implants after mastectomy in the 
course of breast cancer treatment and to determine 
the frequency and time of appearance of implant infec-
tions as well as the etiological agents causing them.
Experimental
Materials and Methods
The study involved 428 patients treated in one onco-
logical center in the years 1998–2018, who underwent 
a total of 648 breast reconstruction procedures using 
artificial implants.
In each case, the implantation procedure was pre-
ceded by the test for MRSA (Methicillin-Resistant 
Staphylococcus aureus) and MSSA (Methicillin-Sensi-
tive Staphylococcus aureus). The swabs taken for this 
purpose came from the nasal vestibule, palms, and 
axilla on the side of the primary tumor of the operated 
patients. The materials for microbiological tests were 
seeded on Columbia Agar supplemented with nalidixic 
acid and amikacin + 5% sheep blood (bioMérieux, 
France) as well as chromogenic Brilliance MRSA 
(Oxoid, UK). After 24 h, the morphology of the colo-
nies was assessed, and a catalase and coagulase assays 
were performed. Also, the sensitivity to methicillin was 
assessed following the current recommendations of the 
National Reference Center for Antimicrobial Suscepti-
bility using the disk diffusion method.
Mupirocin eradication was implemented in cases of 
MRSA colonization in the nasal vestibule. If screen-
ing did not show the presence of MRSA, eradication 
was not performed. On the day before the treatment, in 
the evening hours, a whole-body cleansing was recom-
mended with the use of an antiseptic intended for skin 
decontamination or with the body sponges impregnated 
with an antiseptic (chlorhexidine 4% soap solution). 
On the day of treatment, the whole-body cleansing 
was again recommended with the use of an antiseptic 
intended for skin decontamination. The preparation of 
the patient for a surgery proceeded under the standards 
of nursing practice currently in force at the hospital.
In all patients, perioperative prophylaxis was rou-
tinely used (cefazolin in a dose of 1.0 g in an intrave-
nous injection – given every 8 hours for 5 days). The 
first dose of antibiotics was given up to 30 min before 
the surgery. If the drain remained longer than 5 days, 
antibiotic therapy was prolonged until the drain was 
removed. The procedure for perioperative antibiotic 
prophylaxis was in line with the procedure adopted in 
our center, i.e., the prolonged antibiotic prophylaxis 
in the case of wound drainage. Notwithstanding the 
currently recommended use of 1 dose of antibiotic 
(Phillips et al. 2013), the procedure referred to the 
results of the research presented by Brand et al. (1993), 
which showed greater effectiveness of longer-term use 
of antibacterial drugs in the prophylaxis of infectious 
complications after implantation.
From the group of 428 patients with artificial 
implants used for breast reconstruction, 44 patients were 
selected for the analysis when it was necessary to remove 
the implant, which accounted for 10.3% of the patients 
that underwent surgery. In two out of the 44 patients 
(4.5%), this occurred twice (after twice reconstructed 
breast, with a time interval between subsequent surgi-
cal procedures – 26 and 27 months, respectively), in 
one patient (2.3%), the above situation concerned the 
reconstruction of both breasts (carried out on two dif-
ferent dates – with an interval of 20 months). In none 
of these three patients were signs of infection of the 
surgical site before the second surgery. Thus, the total 
number of removals of implants concerned 47 cases. 
This accounted for 7.3% of all surgical procedures asso-
ciated with generative treatment after implantation of 
an artificial breast implant. The incidence of infection 
was found in 39 cases, which accounted for 6.0% of all 
reconstructive procedures. Further epidemiological 
analyses were based on the number of the performed 
procedures, which resulted in the loss of the implant.
In 20 cases (42.6%), the need to remove the implant 
concerned immediate breast reconstruction surgery, 
while in the remaining 27  cases (57.4%), deferred 
reconstruction had been performed. The type of recon-
structive implant used during the procedure (expander, 
expander prosthesis, or final prosthesis) as well as the 
duration of the procedure (immediate or deferred 
reconstruction) was the result of the current organi-
zational arrangements for treatment and financing of 
the surgical procedures. They were not the result of the 
planned choice of the patients.
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In 46 cases, the reconstruction of the amputated 
breast gland consisted of the insertion of an implant 
in the large pocket created behind the pectoral muscle. 
In one case, the patient’s tissues were used to cover the 
implant (pedunculated skin-muscle flap taken from 
the latissimus dorsi muscle).
In 13 cases (27.7%), the reconstruction was pre-
ceded by chemotherapy and radiotherapy, in one case 
(2.1%) – by radiotherapy (this was the case in most 
patients who underwent restorative treatment in the 
deferred mode). In 13 cases (27.7%) included in the 
study, the patients required pre-operative chemother-
apy (regardless of the mode of reconstruction). In the 
remaining patients, the surgery was not preceded by 
any other type of anticancer treatment (in most cases, 
these were immediate reconstruction treatments), as it 
is presented in Table I.
Data were collected on demographics, histopatho-
logical diagnosis, stage of cancer, concomitant diseases, 
surgery performed, implant characteristics, reasons for 
implant removal, and etiology of infections.
The reasons for the removal of the breast implants 
were determined, including the frequency of infectious 
complications. Infection of the implant was defined 
as surgical site infection (SSI) on the basis of clinical 
symptoms of infection when at least one of the following 
criteria was met: the purulent secretion from the drain 
placed in the operating space; tissue infection confirmed 
during reoperation; isolation of microorganisms from 
aseptically collected exudate/operated space, the pres-
ence of local symptoms such as redness and inflamma-
tory infiltration, pain and elevated body temperature, as 
well as diagnosis of infection given by a doctor. Infec-
tion occurring up to 30 days after the implantation pro-
cedure was categorized as early surgical site infection, 
while all other cases, i.e. appearing at 31 days and later, 
were defined as late surgical site infections. The division 
into early and late infection was in line with Lankie-
wicz et al. (2012), Phillips et al. (2016), and Sinha et al. 
(2017). In our study, with infections defined as late, the 
endpoint of follow-up was the diagnosis of infection/
implant loss. At the same time, within the late infections 
category, two additional groups of patients were created 
based on the infection development period; in the first 
group infection developed within 31 and 90 days, in the 
second group – after 90 days. All infections were classi-
fied as deep surgical site infections.
The material collected for microbiological tests was 
seeded on solid media: Columbia agar with a supple-
ment of 5% sheep blood (bioMérieux, France), Mac-
Conkey agar (bioMérieux, France), Columbia agar 
supplemented with nalidixic acid and amikacin with 
a supplement of 5% sheep blood (bioMérieux, France), 
D-Coccosel agar (bioMérieux, France), Cetrymide agar 
(bioMérieux, France), chromogenic medium for the 
identification of MRSA (Oxoid, UK) as well as the liq-
uid medium Trypticase Soy Broth (bioMérieux, France). 
Incubation was carried out at 35 ± 2°C for 16–24 h. In 
the absence of microbial growth on solid media, incuba-
tion was continued for a further 16–24 h. In addition, 
the broth was seeded on solid media: Columbia Agar 
+ 5% sheep blood and MacConkey agar (bioMérieux, 
France). The identification of microorganisms was car-
ried out using the Vitek 2 Compact system (bioMérieux, 
US) as well as using conventional tests to identify Gram-
positive cocci and Gram-negative bacilli: the assessment 
of catalase and coagulase production, degradation of 
esculin in the presence of bile salts, production of pyrro-
lidonyl peptidase in the PYR test, growth in broth con-
taining 6.5% NaCl and production of oxidase, growth 
in Trypticase Soy Broth at 42°C, and arginine dihydro-
lase production. The procedures were developed based 
on the Clinical Microbiology Procedures Handbook 
(Isenberg 2004). The susceptibility of staphylococci to 
methicillin was assessed following the current recom-
mendations of the National Reference Center for Anti-
microbial Susceptibility using the disk diffusion method.
The etiology of microorganisms was analyzed con-
cerning the type of surgery (immediate and deferred 
reconstruction) as well as with the oncological therapy 
before implantation vs. absence of such therapy.
Statistical analysis of the relationship between the 
profile of microorganisms and the type of reconstruc-
tion and oncological therapy administered before 
implantation (chemotherapy or radiotherapy) was car-
ried out using Fisher’s exact test. Differences were con-
sidered statistically significant at p < 0.05. The results 
are also shown as a percentage, median and average of 
the results recorded.
Pre-implantation treatment:
– RTH  1 (2.1)
– CHTH 13 (27.7)
– RTH+CHTH 13 (27.7)
– No treatment 19 (40.4)
– No data  1 (2.1)
Post-implantation treatment:
– RTH  1 (2.1)
– CHTH  4 (8.5)
– RTH+CHTH  1 (2.1)
– No treatment 40 (85.1)
– No data  1 (2.1)
Table I
Characteristics of pre- and post-implantation treatment
of cancer patients.
RTH – radiotherapy, CHTH – chemotherapy
Characteristic Number of cases n = 47n (%)
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Results
The average age of patients was 48.4 years (range 
from 27 to 64 years, median 49.0). The mean body mass 
index (BMI) was 26.1 kg/m2 (range from 17.7 to 35.2, 
median 26.1). In 6.4% of patients, diabetes was con-
firmed, and 4.3% of them were active smokers. Among 
the patients, eight (17.0%) were MSSA carriers; none of 
them was a carrier of MRSA. The average time before 
removal of the implant was 601 days (range 14–9102, 
median 113 days). The average follow-up time was 601 
days. More than half of the patients have an increased 
BMI, about 1/3 of them received pre-operative radio-
therapy; there were active smokers and people with 
diabetes. The coexistence of recognized risk factors 
increased the danger of infection. The detailed clini-
cal characteristics of patients are presented in Table II.
In 83.0% (39/47) of cases, the reason for removal 
of the implant was an infection, in 8.5% (4/47) local 
recurrence of breast cancer, and in 4.3% (2/47) damage 
(a leakage) of the implant. In 2.1% (1/47) of cases, the 
reason for removal of the implant was post-operative 
pain, in 2.1% (1/47) the reason was unknown. The rea-
sons for implant removal are shown in Table III.
The only reason for removal of the implant up 
to 30 days after the reconstructive treatment was an 
infection, which appeared in six of the cases analyzed 
(12.8%). The implants were removed on average after 
18 days (median 16 days, range 14–27 days) after the 
reconstructive procedure. In 23.4% (11/47) of cases, the 
infection was recognized between 31 and 90 days after 
surgery, in 36.2% (17/47) between 91 and 365 days after 
surgery, and in 10.6% (5/47) after a period longer than 
one year. Up to 90 days after surgery, 17/39 (43.6%) 
infections were identified, up to one year –  34/39 
(87.2%) cases, and after this period – 5/39 (12.8%) cases. 
The late infections (> 30 days) appeared on average after 
329 days (median 115 days, range 35–4914 days).
The remaining, non-infectious complications that 
caused the removal of the implant in seven cases 
(14.9%) appeared on average after 2465 days (median 
Table II
Clinical and histopathological characteristics of patients with 
implant loss, and the type of reconstruction.
Type of carcinoma
Ductal carcinoma 36 (76.6)
Lobular carcinoma  2 (4.3)
Other forms of invasive cancer  3 (6.4)
DCIS  4 (8.5)
No data  2 (4.3)
Clinical stage (cTNM)
IA 14 (29.8)
IIA 17 (36.2)
IIB  5 (10.6)
IIIA  2 (4.3)
IIIB  1 (2.1)
No data  8 (17.0)
Diabetes
Yes  3 (6.4)
No 44 (93.6)
Nicotinism
Yes  2 (4.3)
No 36 (76.6)
No data  9 (19.1)
BMI [kg/m2]
< 25 21 (44.7)
≥ 25 26 (55.3)
MSSA carrier
Yes  8 (17.0)
No 26 (55.3)
No data 13 (27.7)
Type of reconstruction
Immediate 20 (42.6)
Deferred 27 (57.4)
Type of implant
Expander 23 (48.9)
Expander prosthesis  8 (17.0)
Prosthesis  5 (10.6)
Expander prosthesis/prosthesis
(2nd stage of reconstruction 11 (23.4)
– replacement of implant after earlier
implantation of expander)
BMI – Body Mass Index
MSSA – Methicillin-Sensitive Staphylococcus aureus
DCIS – Ductal Carcinoma In Situ
cTNM – Clinical TNM (classification system of malignant tumors 
   – tumor, node, metastasis)
Characteristics Number of cases n = 47n (%)
Infection
Early (≤ 30 days)  6 (12.8)
Late (> 30 days)
31–90 days 11 (23.4)
91–365 days 17 (36.2)
> 365 days  5 (10.6)
– Local recurrence of breast cancer  2 (4.3)
– Local recurrence of breast cancer
  in the chest wall 
 2 (4.3)
– Postoperative pain   1 (2.1)
– Leakage of prosthesis/expander
  prosthesis  
 2 (4.3)
– No data  1 (2.1)
Table III
Characteristics of postoperative complications.
Characteristics Number of cases n = 47n (%)
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1630 days, range 239–9102). The longest time inter-
val between reconstruction and implant removal was 
9102 days and it was due to the leakage of the prosthe-
sis. The shortest time interval was 239 days, and the 
removal of the implant was due to the recurrence of 
local breast cancer in the chest wall.
In five out of 39 cases (12.8%), the infection was 
diagnosed only based on clinical symptoms without 
microbiological diagnosis and no microorganisms were 
grown in six out of 39 cases of infections (15.4%). In 
24 out of 28 (85.7%) microbiologically confirmed cases 
of infection, bacteria were present in monoculture, in 
four cases (14.3%) polybacterial infections were found. 
Among the etiological agents were: coagulase-negative 
staphylococci (31.3%), Staphylococcus aureus (18.7%), 
Enterococcus faecalis (9.4%), Enterobacter cloacae 
(18.8%), Pseudomonas aeruginosa (12.5%), and Acineto-
bacter lwoffii (3.1%). Other fermenting Gram-negative 
rods accounted for 6.2%. The cultured and identified 
etiological agents of infections are shown in Fig. 1.
There were no statistically significant differences in 
the etiology of microorganisms (cocci vs rods) between 
the groups of patients after immediate and deferred 
reconstruction and between cancer patients treated 
before implantation (radiotherapy and/or chemother-
apy) vs. cancer patients that do not receive any treat-
ment (p > 0.05).
Discussion
In this study, we show that infections were the 
most common reason of the removal of the implants 
after generative treatment in breast cancer and were 
responsible for the loss of the implant in 83.0% of the 
cases analyzed. The prevalence of breast implant infec-
tion in this study was 6.0% of implantation. Of the 
infections diagnosed, 87.0% appeared within one year 
of implantation; however, less than half of the infec-
tions developed within 90 days of the reconstructive 
surgery, while up to 30 days – about 13.0% of infec-
tions were diagnosed. Non-infectious complications 
caused the loss of the implant in about 15.0% of the 
cases analyzed.
In the available literature, infection after the breast 
reconstruction surgery appeared with varying fre-
quency and their etiological agents were different. 
This is related to the adopted definition of infection, 
the period of time for surveillance, the perioperative 
prophylaxis applied, and the composition of micro-
biota inhabiting the operated area (Weichman et al. 
2013). The time of observation significantly influ-
ences the obtained results. In the studies of Olsen et al. 
(2017) on a large group of respondents, approximately 
17 000 patients undergoing mastectomy, the incidence 
of SSI up to 90  days after surgery was 3.2–8.9% and 
was dependent on the type of reconstruction. In the 
opinion of the authors cited, it is necessary to carry 
out the infection surveillance up to 90 days after sur-
gery, since the shorter period of observation, limited 
to 30 days, leads to an underestimation of the rate of 
infection. Similarly, Lankiewicz et al. (2012) found, 
however, on a smaller group of patients comprised of 
54  women undergoing mastectomy with immediate 
reconstruction with an implant, that only about 1/2 
of the diagnosed SSI developed within 30  days after 
surgery. Viola et al. (2016), in single-center retrospec-
tive studies involving over 3000 patients, found that 
only 30.0% of all SSIs were diagnosed within the first 
30 days after a simultaneous reconstruction using a tis-
sue expander. In our work, we found lower rates than 
the quoted authors (Lankiewicz et al., 2012; Viola et al. 
2016) regarding infection within 30 days after recon-
structive surgery. When we limited observation to one 
month after the procedure we were able to detect only 
1/8 of the implant infections confirmed.
Fig. 1. Bacterial species isolated from the breast artificial implants infections.
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The reasons for the variability in the period when 
the infections appeared were probably related to the 
eligibility criteria for the reconstructive surgery (the 
patient’s profile), the type of surgery performed, the 
experience of the center performing the implant treat-
ments, as well as the prophylactic treatment used. In 
our work, we confirmed that the observation of infec-
tions limited to 30 days after surgery was insufficient, as 
was the 90-days observation. It seems that the optimal 
time could be a one-year observation. In our study, this 
allowed the detection of approximately 90% of infec-
tions. The necessity to monitor for complications after 
breast reconstruction during one year after surgery, 
instead of 30  days, has also been indicated by other 
researchers (Blough et al. 2018), who used individual-
ized tools to assess the risk of post-surgery complica-
tions within one year of breast reconstruction.
The fact that the number of infections within 
30 days in the cases we analyzed was lower than the 
numbers appearing in the studies already published 
may be related to the strict epidemiological supervi-
sion carried out in our hospital and the prophylaxis to 
prevent perioperative infections.
According to the hospital antibiotic policy, the 
patients studied in the current work received prophy-
lactically a first generation cephalosporin in therapy 
extended for five days, or until the drain was removed 
due to the increased SSI risk associated with drain-
age (Araco et al. 2007). However, currently, many 
authors advise against such a procedure, pointing to 
the side effects that accompany it, namely the increase 
in resistance among microorganisms responsible for 
SSI (McCullough et al. 2016). In accordance with the 
idea of perioperative prophylaxis, a single dose of the 
first-generation cephalosporin is sufficient to ensure 
the proper concentration of the antibiotic at the inci-
sion site and to prevent infections mainly caused by 
methicillin-sensitive staphylococci (Pittet et al. 2005). 
Under the recommendations of scientific societies, 
it is also not suggested to continue treatment with 
antibiotics after discharge from the hospital, and the 
guidelines of the American Society of Plastic Surgeons 
recommend discontinuation of antibiotics at 24 hours 
after surgery. Nevertheless, a review of publications 
(Phillips et al. 2016; Viola et al. 2016) shows that the 
use of prolonged antibiotic therapy by surgeons, both 
during hospitalization and after discharge from the hos-
pital, is quite common.
In addition to the prophylactic use of antibiot-
ics, a  screening test for S. aureus was introduced as 
a standard in our hospital. When colonization with 
MRSA strain is confirmed, mupirocin is applied nasally 
without performing tests confirming the effectiveness 
of eradication. However, in the cases analyzed in the 
current work, no MRSA carriers were found. Whereas, 
concerning the colonization with MSSA strains, we 
assumed that the perioperative prophylaxis with the 
first-generation cephalosporin is sufficient protec-
tion, with its MSSA spectrum of action. It should be 
emphasized that screening for S. aureus in the group 
of patients undergoing reconstruction is not recom-
mended. According to the recommendations for 
microbiological screening tests in hospitalized patients 
(Fleischer et al. 2017), investigation for the carriage of 
S. aureus is recommended only before cardiac surgery, 
implantation of joint prostheses and spine procedures, 
as well as in centers with incidence of SSI caused by 
S. aureus higher than the average reported in literature, 
mainly in neurosurgery and vascular surgery. Patients 
qualified for breast reconstruction do not meet the cri-
teria given in these recommendations. Nevertheless, 
within the framework of the perioperative infections 
prevention carried out in our center, such examination 
was undertaken. In the current work, we diagnosed 
MSSA carriers in 17.0% of the cases. In one case, the 
host had to remove the implant 14 days after surgery 
due to infection caused by S. aureus. In other cases, the 
infection caused by MSSA occurred in the late period, 
on average more than one year after surgery, similarly 
as in a patient with an MRSA-induced infection.
In the available literature on implant infections, 
among the etiological agents of infections after breast 
reconstruction, the microbiota of the skin and at the 
mouth of the milk ducts were isolated (coagulase-
negative Staphylococcus, mainly S. epidermidis and 
coagulase-positive S. aureus) (Chidester et al. 2016; 
McCullough et al. 2016; Viola et al. 2016). These spe-
cies adhere to the smooth surfaces of biomaterials, and 
may also colonize the skin. They demonstrate the ability 
to form a  biofilm, which protects them against the 
host’s immune system and antibiotics (Vacheethasanee 
et al. 1998; Costerton et al. 1999; Chessa et al. 2016; 
Conte et al. 2018).
In our work, staphylococci constituted 50% of the 
isolated microorganisms. They were in a lower percent-
age than in the studies by Seng et al. (2015) but similar 
to the results obtained in Song et al. (2017) (respec-
tively: 71.0%, and 50.0%). In three cases (9.4%), we iso-
lated E. faecalis that can adhere, modify the immune 
response, and form biofilms (Prażmo et al. 2016); 
however, these species are rarely the etiological agent 
of implant infections. In the available literature, one can 
find only a few reports about the participation of these 
microorganisms in wound infections after immediate 
breast reconstruction (Abedi et al. 2016).
The incidence of infections caused by Gram-nega-
tive rods is varied. In the work of Feldman et al. (Feld-
man et al. 2010) concerning early infections of breast 
implants, Gram-negative rods accounted for 6.0% of 
the microorganisms isolated. Seng et al. (2015) also 
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confirmed the participation of these bacteria in implant 
infections: Gram-negative rods were identified in 27.0% 
of cases, and P. aeruginosa was the second most com-
monly isolated microorganism. In turn, in the work 
of Chidester et al. (2016) P. aeruginosa was the most 
common causative agent of infections and accounted 
for 26.8% of them. Research carried out by Song et al. 
(2017) indicates the involvement of A. baumanii in 
infections alongside with P. aeruginosa.
In our work more frequently than in the previous 
studies (Feldman et al. 2010; Seng et al. 2015; Chidester 
et al. 2016; Song et al. 2017), Gram-negative bacilli were 
isolated. They constituted a total of 40.6% of the bacte-
rial isolates. The most commonly isolated rods were 
E. cloacae (18.8%), and P. aeruginosa (12.5%). These 
microorganisms secrete extracellular polymers form-
ing a complex matrix of biofilm. The biofilm matrix 
plays an important role in survival in tissues and evad-
ing the response of the body’s immune system, which 
promotes the development of the infection despite 
the use of antibiotics (Donlan and Costerton 2002). The 
occurrence of Gram-negative bacilli, naturally resistant 
to the first-generation cephalosporin, may be associated 
with the perioperative prophylaxis. Our work did not 
show the dependence of the etiology of microorgan-
isms (cocci vs. rods) on the type of reconstruction or 
oncological treatment.
Polybacterial infections are not associated with 
implants. However, in this work, in four cases (14.3%) 
we showed the presence of the polybacterial infections. 
Similar results were obtained by Seng et al. (2015), as 
well as Viola et al. (2016), the percentage of polybac-
terial infections reached 19.0 and 17.0%, respectively, 
among all diagnosed infections. In the cases analyzed 
by us, two polybacterial infections related to patients 
treated with radiotherapy. Radiotherapy is an impor-
tant risk factor for the occurrence of infection through 
damage to the skin and other tissues, which may affect 
the microbiota. In over 1/3 of cases, the adjuvant 
treatment was radiotherapy (in 14 cases before recon-
struction surgery, in 2 cases after surgery). However, 
in only one case for the reconstruction of the breast 
beside the implantation, autologous tissues were used 
(lobe from the latissimus dorsi muscle). According 
to the current standard of diagnostic and therapeutic 
procedures, this is the recommended method of treat-
ment (Bocian et al. 2016). This indicates the need to 
use more complex restorative treatments in the future 
(especially the use of flap techniques in patients requir-
ing radiation therapy).
The existence of a significant risk of complications 
(especially infectious) related to radiotherapy was 
shown by Jagsi et al. (2016) and among the most com-
mon adverse effects, they mention an increased risk of 
wound infection between 7 and 24 months after sur-
gery, and consequently the requirement to remove the 
implant. Similar observations were also presented by 
other authors (Momoh et al. 2014; Blough et al. 2018). 
In our work, the median time to remove the implant 
after using radiotherapy was 3–4 months after surgery.
In addition to radiotherapy, factors that increase 
the risk of infection complications according to War-
ren Peled et al. (2010) also include adjuvant chemother-
apy. However, in newer works, this relationship is not 
shown. The lack of influence of the time of the chemo-
therapy administration on the risk of SSI (pre-operative 
vs. post-operative vs. pre- and post- vs. non-chemo-
therapy) was demonstrated by Chattha et al. (2018).
In approximately 1/6 of the cases discussed by us, 
there was no confirmation of microbiological infection, 
despite the presence of clinical symptoms of wound 
infection. The probable cause of the negative culture 
results was an occurrence of rare microorganisms, 
which do not grow on classical microbiological media 
and also difficulty in culturing microorganisms pre-
sent in biofilms or the presence of microorganisms with 
special nutritional requirements (Pajkos et al 2003). 
This is confirmed by the results of the research made 
using molecular biology methods. The use of molecular 
techniques as well as gene sequencing omits the culture 
and leads to an increase in the recognition of infec-
tions (Romero et al. 2017). Management of infections 
in oncological patients should now include extended 
microbiological diagnostics to detect hard growing 
or non-cultivated microorganisms (Pittet et al. 2005; 
Al-Halabi et al. 2018).
Infections remain the most common reason for 
removing implants and are a serious complication of 
reconstruction during the treatment of breast cancer. 
The existence of risk factors for infection, the diver- 
sity of bacterial species that cause the implant infec- 
tion, their potential for biofilm formation and natural 
resistance to selected groups of antibiotics, as well as 
the long time of infection development pose a  great 
challenge for the effective treatment of implant infec-
tions, which in turn leads to the removal of the implant. 
The introduction of standardized data collection pro- 
tocols in the prospective studies, especially in special-
ized breast cancer centers, may be helpful in the iden-
tification of the factors that increase the risk of surgical 
site infection after reconstruction, determination the 
etiology of infections, establishment of the optimal 
perioperative prophylaxis, in empirical therapy, as well 
as in post-hospital outpatient care. This should result 
in lower SSI rates.
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